CTLA4 and melanoma: An alternative mechanism of action of some ICBs would be to directly deplete cells expressing these markers, as observed with the anti-CTLA-4 ipilumimab, which induces direct elimination of CTLA-4+ regulatory T cells in tumor tissue in patients with melanoma [52].